Global Biosimilars Market : Industry Analysis and Forecast (2019-2027) – by Product, by Type of Manufacturing, by Diseases and by Region

Global Biosimilars Market was valued at US$ 5 Bn in 2019 and is expected to reach US$ 33.65 Bn by 2027, at a CAGR of 26.91 % during the forecast period. The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region. Global-Biosimilars-Market-2 To know about the Research Methodology :- Request Free Sample Report

Global Biosimilars Market Dynamics:

Biosimilars, sometimes referred as biogenerics, are highly close versions of biologic medicines made from living microorganisms found in animal or plant cells that are already licensed by the U.S. Food and Drug Administration (FDA). The term “generic” refers only to traditional or small molecule drugs that are biologically parallel to an already approved small molecule drug. They are also similar to the reference biological product in terms of safety, purity, and potency, but may have minor differences in clinically inactive components. Biosimilars development and validation from the reference biological products is a critical part of the overall development process. Regulations on biosimilars play key role to continue the viability and balance between original and biosimilars products. Different regulatory authorities such as European Medicines Agency (EMA) and Food and Drug Administration (FDA) actively control the biosimilar's commercialization and development. The growth of the biosimilars market is highly driven by, increasing incidences of chronic diseases such as diabetes, cancer, and other and strategic collaborations resulting in enhanced productivity and clinical trial activities. Moreover, increasing patient access to treatment due to its less cost over the biological drugs, reassuring pipeline of biosimilars with the expiration of biologics patents, and an increased demand for such drugs in the developing countries, these are the primary factors will drive the biosimilar global market during forecast period. On the other hand, A complex manufacturing process coupled with the high cost of development, and limited availability of biosimilar products developmental cost and complexities, strategies from originators and interchangeability concerns, and lack of regulatory guidelines, factors will hamper the market of biosimilars in the near future.

Global Biosimilars Market Segment Analysis:

On the basis of product, the recombinant glycosylated proteins segment including monoclonal antibody, recombinant peptides, and erythropoietin contributed the largest market share in of biosimilars market in 2019 and is expected to grow at the highest rate during the forecast period owing to the cost-effectiveness of biosimilars over biological drugs and wide range therapeutic applications. On the basis of type of manufacturing, the in-house manufacturing segment held largest market share in 2019 and is expected to grow at highest CAGR during forecast period. Most of the key players in the biosimilars market prefer the in-house method for manufacturing as they can develop biosimilars in their own laboratories so it will eliminate shipping and delivery costs. On the basis of diseases, the blood disorder segment held largest share of the market in 2019 and expected to grow at highest rate in forecast period attributed to increasing cases of blood disorders all over the world and low cost of biosimilars compared to biologics. Moreover, an increasing pressure to reduce healthcare expenditure is a major factor contributing to the growth of this segment.

Global Biosimilars Market Regional Analysis:

Europe region held the highest share in the biosimilar market in 2019 and is also expected to grow at the highest rate during the forecast period owing to the number of factors including increasing cases of chronic disorders, the patent expiry of many biological products, the launch of new biosimilars, and the emergence of new market participants, these factors are expected to drive the market of the biosimilar. Europe is followed by the Asia Pacific. Asia Pacific is also is expected to bloom the market of biosimilars at the highest CAGR from 2019 to 2027.

Recent Highlights in Biosimilars Market

• New federal rules are supposed to make biosimilars more accessible. the US Food and Drug Administration has released a bunch of guidelines purposely to fuel the market for biosimilars, generic versions of complex biological drugs, mainly proteins, which are used for treatment of diseases like cancer and autoimmunity. The FDA has already passed 19 biosimilars. • Biosimilars achieving Popularity for Rheumatoid Arthritis predicted by experts in the European League against Rheumatism 2019 Congress. • Canadian advisory council recommended the use of biosimilars in a final report that lays out 60 recommendations for how the country can create a CAN $15.3 billion (about US $11.4 billion) universal, single-payer, public system for pharmaceutical coverage. • Data to be introduced at the European Congress of Rheumatology (EULAR) 2019 highlight real-world evidence confirming the safety and efficacy of anti-TNF biosimilars and high adherence of patients to treatment. • Biogen’s three biosimilar treatments – BENEPALI™ (etanercept), FLIXABI™ (infliximab), and IMRALDI™ (adalimumab) – are estimated to save the European healthcare system 1.8 billion euros in 2019. • Biogen and its collaboration partner Samsung Bioepis are the first companies in Europe to market biosimilars that reference the three most prescribed anti-TNF biologic treatments, with approximately 145,000 patients currently on treatment. The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Biosimilars Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence.

Global Biosimilars Market, Key Highlights:

• Global Biosimilars Market analysis and forecast, in terms of value. • Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Biosimilars Market • Global Biosimilars Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided. • Global Biosimilars Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study. • Global Biosimilars Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation. • Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled. • Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Biosimilars Market are also profiled.

Scope of the Global Biosimilars Market Report: Inquire before buying

Global Biosimilars Market, by Product

• Recombinant non-glycosylated Proteins o Insulin o Recombinant Human Growth Hormone o Granulocyte Colony-stimulating Factor o Interferon • Recombinant Glycosylated Proteins o Erythropoietin o Monoclonal Antibodies  Rituximab  Infliximab  Adalimumab  Other Monoclonal Antibodies o Follitropin o Recombinant Peptides  Glucagon  Calcitonin

Global Biosimilars Market, by Type of Manufacturing

• In-house Manufacturing • Contract Manufacturing

Global Biosimilars Market, by Disease

• Oncology • Blood Disorders • Chronic Diseases • Autoimmune Diseases • Growth Hormone Deficiency • Infectious Diseases • Other Diseases

Global Biosimilars Market, by Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key Players Operating in the Global Biosimilars Market:

• Pfizer • Sandoz International • Teva Pharmaceuticals • Amgen • Biocon • Dr. Reddy’s Laboratories • Celltrion • Samsung Biologics • Eli Lily & Company • Hospira Inc. • ctavis, Inc • Teva Pharmaceutical Industries Ltd. • Cipla Ltd. • Stada Arzneimittel Ag • Wockhardt Ltd • Mylan, Inc. • Biocad • Coherus Bioscience • Boehringer Ingelheim • Fresenius Kabi AG

Global Biosimilars Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.2. Secondary data 2.3.3. Secondary Sources 2.3.4. Primary Research 2.3.5. Data from Primary Sources 2.3.6. Breakdown of Primary Sources 3. Executive Summary: Global Biosimilars Market, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Global Biosimilars Market Industry Trends 4.8.Global Biosimilars Market Competitive Landscape 5. Supply Side and Demand Side Indicators 6. Global Biosimilars Market Analysis and Forecast 6.1. Global Biosimilars Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Biosimilars Market Analysis and Forecast, By Product 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Biosimilars Market Value Share Analysis, By Product 7.4. Global Biosimilars Market Size (US$ Bn) Forecast, By Product 7.5. Global Biosimilars Market Analysis, By Product 7.6. Global Biosimilars Market Attractiveness Analysis, By Product 8. Global Biosimilars Market Analysis and Forecast, By Type of Manufacturing 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Biosimilars Market Value Share Analysis, By Type of Manufacturing 8.4. Global Biosimilars Market Size (US$ Bn) Forecast, By Type of Manufacturing 8.5. Global Biosimilars Market Analysis, By Type of Manufacturing 8.6. Global Biosimilars Market Attractiveness Analysis, By Type of Manufacturing 9. Global Biosimilars Market Analysis and Forecast, By Disease 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Biosimilars Market Value Share Analysis, By Disease 9.4. Global Biosimilars Market Size (US$ Bn) Forecast, By Disease 9.5. Global Biosimilars Market Analysis, By Disease 9.6. Global Biosimilars Market Attractiveness Analysis, By Disease 10. Global Biosimilars Market Analysis, by Region 10.1. Global Biosimilars Market Value Share Analysis, by Region 10.2. Global Biosimilars Market Size (US$ Bn) Forecast, by Region 10.3. Global Biosimilars Market Attractiveness Analysis, by Region 11. North America Biosimilars Market Analysis 11.1. Key Findings 11.2. North America Biosimilars Market Overview 11.3. North America Biosimilars Market Value Share Analysis, By Product 11.4. North America Biosimilars Market Forecast, By Product 11.4.1. Recombinant Non-glycosylated Proteins 11.4.1.1. Insulin 11.4.1.2. Recombinant Human Growth Hormone 11.4.1.3. Granulocyte Colony-stimulating Factor 11.4.1.4. Interferon 11.4.2. Recombinant Glycosylated Proteins 11.4.2.1. Erythropoietin 11.4.2.2. Monoclonal Antibodies 11.4.2.2.1. Rituximab 11.4.2.2.2. Infliximab 11.4.2.2.3. Adalimumab 11.4.2.2.4. Other Monoclonal Antibodies 11.4.2.3. Follitropin 11.4.2.4. Recombinant Peptides 11.4.2.4.1. Glucagon 11.4.2.4.2. Calcitonin 11.5. North America Biosimilars Market Value Share Analysis, By Type of Manufacturing 11.6. North America Biosimilars Market Forecast, By Type of Manufacturing 11.6.1. In-house Manufacturing 11.6.2. Contract Manufacturing 11.7. North America Biosimilars Market Value Share Analysis, By Disease 11.8. North America Biosimilars Market Forecast, By Disease 11.8.1. Oncology 11.8.2. Blood Disorders 11.8.3. Chronic Diseases 11.8.4. Autoimmune Diseases 11.8.5. Growth Hormone Deficiency 11.8.6. Infectious Diseases 11.8.7. Other Diseases 11.9. North America Biosimilars Market Value Share Analysis, by Country 11.10. North America Biosimilars Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Biosimilars Market Analysis, by Country 11.12. U.S. Biosimilars Market Forecast, By Product 11.12.1. Recombinant Non-glycosylated Proteins 11.12.1.1. Insulin 11.12.1.2. Recombinant Human Growth Hormone 11.12.1.3. Granulocyte Colony-stimulating Factor 11.12.1.4. Interferon 11.12.2. Recombinant Glycosylated Proteins 11.12.2.1. Erythropoietin 11.12.2.2. Monoclonal Antibodies 11.12.2.2.1. Rituximab 11.12.2.2.2. Infliximab 11.12.2.2.3. Adalimumab 11.12.2.2.4. Other Monoclonal Antibodies 11.12.2.3. Follitropin 11.12.2.4. Recombinant Peptides 11.12.2.4.1. Glucagon 11.12.2.4.2. Calcitonin 11.13. U.S. Biosimilars Market Forecast, By Type of Manufacturing 11.13.1. In-house Manufacturing 11.13.2. Contract Manufacturing 11.14. U.S. Biosimilars Market Forecast, By Disease 11.14.1. Oncology 11.14.2. Blood Disorders 11.14.3. Chronic Diseases 11.14.4. Autoimmune Diseases 11.14.5. Growth Hormone Deficiency 11.14.6. Infectious Diseases 11.14.7. Other Diseases 11.15. Canada Biosimilars Market Forecast, By Product 11.15.1. Recombinant Non-glycosylated Proteins 11.15.1.1. Insulin 11.15.1.2. Recombinant Human Growth Hormone 11.15.1.3. Granulocyte Colony-stimulating Factor 11.15.1.4. Interferon 11.15.2. Recombinant Glycosylated Proteins 11.15.2.1. Erythropoietin 11.15.2.2. Monoclonal Antibodies 11.15.2.2.1. Rituximab 11.15.2.2.2. Infliximab 11.15.2.2.3. Adalimumab 11.15.2.2.4. Other Monoclonal Antibodies 11.15.2.3. Follitropin 11.15.2.4. Recombinant Peptides 11.15.2.4.1. Glucagon 11.15.2.4.2. Calcitonin 11.16. Canada Biosimilars Market Forecast, By Type of Manufacturing 11.16.1. In-house Manufacturing 11.16.2. Contract Manufacturing 11.17. Canada Biosimilars Market Forecast, By Disease 11.17.1. Oncology 11.17.2. Blood Disorders 11.17.3. Chronic Diseases 11.17.4. Autoimmune Diseases 11.17.5. Growth Hormone Deficiency 11.17.6. Infectious Diseases 11.17.7. Other Diseases 11.18. North America Biosimilars Market Attractiveness Analysis 11.18.1. By Product 11.18.2. By Type of Manufacturing 11.18.3. By Disease 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Development 12. Europe Biosimilars Market Analysis 12.1. Key Findings 12.2. Europe Biosimilars Market Overview 12.3. Europe Biosimilars Market Value Share Analysis, By Product 12.4. Europe Biosimilars Market Forecast, By Product 12.4.1. Recombinant Non-glycosylated Proteins 12.4.1.1. Insulin 12.4.1.2. Recombinant Human Growth Hormone 12.4.1.3. Granulocyte Colony-stimulating Factor 12.4.1.4. Interferon 12.4.2. Recombinant Glycosylated Proteins 12.4.2.1. Erythropoietin 12.4.2.2. Monoclonal Antibodies 12.4.2.2.1. Rituximab 12.4.2.2.2. Infliximab 12.4.2.2.3. Adalimumab 12.4.2.2.4. Other Monoclonal Antibodies 12.4.2.3. Follitropin 12.4.2.4. Recombinant Peptides 12.4.2.4.1. Glucagon 12.4.2.4.2. Calcitonin 12.5. Europe Biosimilars Market Value Share Analysis, By Type of Manufacturing 12.6. Europe Biosimilars Market Forecast, By Type of Manufacturing 12.6.1. In-house Manufacturing 12.6.2. Contract Manufacturing 12.7. Europe Biosimilars Market Value Share Analysis, By Disease 12.8. Europe Biosimilars Market Forecast, By Disease 12.8.1. Oncology 12.8.2. Blood Disorders 12.8.3. Chronic Diseases 12.8.4. Autoimmune Diseases 12.8.5. Growth Hormone Deficiency 12.8.6. Infectious Diseases 12.8.7. Other Diseases 12.9. Europe Biosimilars Market Value Share Analysis, by Country 12.10. Europe Biosimilars Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Biosimilars Market Analysis, by Country 12.12. Germany Biosimilars Market Forecast, By Product 12.12.1. Recombinant Non-glycosylated Proteins 12.12.1.1. Insulin 12.12.1.2. Recombinant Human Growth Hormone 12.12.1.3. Granulocyte Colony-stimulating Factor 12.12.1.4. Interferon 12.12.2. Recombinant Glycosylated Proteins 12.12.2.1. Erythropoietin 12.12.2.2. Monoclonal Antibodies 12.12.2.2.1. Rituximab 12.12.2.2.2. Infliximab 12.12.2.2.3. Adalimumab 12.12.2.2.4. Other Monoclonal Antibodies 12.12.2.3. Follitropin 12.12.2.4. Recombinant Peptides 12.12.2.4.1. Glucagon 12.12.2.4.2. Calcitonin 12.13. Germany Biosimilars Market Forecast, By Type of Manufacturing 12.13.1. In-house Manufacturing 12.13.2. Contract Manufacturing 12.14. Germany Biosimilars Market Forecast, By Disease 12.14.1. Oncology 12.14.2. Blood Disorders 12.14.3. Chronic Diseases 12.14.4. Autoimmune Diseases 12.14.5. Growth Hormone Deficiency 12.14.6. Infectious Diseases 12.14.7. Other Diseases 12.15. U.K. Biosimilars Market Forecast, By Product 12.15.1. Recombinant Non-glycosylated Proteins 12.15.1.1. Insulin 12.15.1.2. Recombinant Human Growth Hormone 12.15.1.3. Granulocyte Colony-stimulating Factor 12.15.1.4. Interferon 12.15.2. Recombinant Glycosylated Proteins 12.15.2.1. Erythropoietin 12.15.2.2. Monoclonal Antibodies 12.15.2.2.1. Rituximab 12.15.2.2.2. Infliximab 12.15.2.2.3. Adalimumab 12.15.2.2.4. Other Monoclonal Antibodies 12.15.2.3. Follitropin 12.15.2.4. Recombinant Peptides 12.15.2.4.1. Glucagon 12.15.2.4.2. Calcitonin 12.16. U.K. Biosimilars Market Forecast, By Type of Manufacturing 12.16.1. In-house Manufacturing 12.16.2. Contract Manufacturing 12.17. U.K. Biosimilars Market Forecast, By Disease 12.17.1. Oncology 12.17.2. Blood Disorders 12.17.3. Chronic Diseases 12.17.4. Autoimmune Diseases 12.17.5. Growth Hormone Deficiency 12.17.6. Infectious Diseases 12.17.7. Other Diseases 12.18. France Biosimilars Market Forecast, By Product 12.18.1. Recombinant Non-glycosylated Proteins 12.18.1.1. Insulin 12.18.1.2. Recombinant Human Growth Hormone 12.18.1.3. Granulocyte Colony-stimulating Factor 12.18.1.4. Interferon 12.18.2. Recombinant Glycosylated Proteins 12.18.2.1. Erythropoietin 12.18.2.2. Monoclonal Antibodies 12.18.2.2.1. Rituximab 12.18.2.2.2. Infliximab 12.18.2.2.3. Adalimumab 12.18.2.2.4. Other Monoclonal Antibodies 12.18.2.3. Follitropin 12.18.2.4. Recombinant Peptides 12.18.2.4.1. Glucagon 12.18.2.4.2. Calcitonin 12.19. France Biosimilars Market Forecast, By Type of Manufacturing 12.19.1. In-house Manufacturing 12.19.2. Contract Manufacturing 12.20. France Biosimilars Market Forecast, By Disease 12.20.1. Oncology 12.20.2. Blood Disorders 12.20.3. Chronic Diseases 12.20.4. Autoimmune Diseases 12.20.5. Growth Hormone Deficiency 12.20.6. Infectious Diseases 12.20.7. Other Diseases 12.21. Italy Biosimilars Market Forecast, By Product 12.21.1. Recombinant Non-glycosylated Proteins 12.21.1.1. Insulin 12.21.1.2. Recombinant Human Growth Hormone 12.21.1.3. Granulocyte Colony-stimulating Factor 12.21.1.4. Interferon 12.21.2. Recombinant Glycosylated Proteins 12.21.2.1. Erythropoietin 12.21.2.2. Monoclonal Antibodies 12.21.2.2.1. Rituximab 12.21.2.2.2. Infliximab 12.21.2.2.3. Adalimumab 12.21.2.2.4. Other Monoclonal Antibodies 12.21.2.3. Follitropin 12.21.2.4. Recombinant Peptides 12.21.2.4.1. Glucagon 12.21.2.4.2. Calcitonin 12.22. Italy Biosimilars Market Forecast, By Type of Manufacturing 12.22.1. In-house Manufacturing 12.22.2. Contract Manufacturing 12.23. Italy Biosimilars Market Forecast, By Disease 12.23.1. Oncology 12.23.2. Blood Disorders 12.23.3. Chronic Diseases 12.23.4. Autoimmune Diseases 12.23.5. Growth Hormone Deficiency 12.23.6. Infectious Diseases 12.23.7. Other Diseases 12.24. Spain Biosimilars Market Forecast, By Product 12.24.1. Recombinant Non-glycosylated Proteins 12.24.1.1. Insulin 12.24.1.2. Recombinant Human Growth Hormone 12.24.1.3. Granulocyte Colony-stimulating Factor 12.24.1.4. Interferon 12.24.2. Recombinant Glycosylated Proteins 12.24.2.1. Erythropoietin 12.24.2.2. Monoclonal Antibodies 12.24.2.2.1. Rituximab 12.24.2.2.2. Infliximab 12.24.2.2.3. Adalimumab 12.24.2.2.4. Other Monoclonal Antibodies 12.24.2.3. Follitropin 12.24.2.4. Recombinant Peptides 12.24.2.4.1. Glucagon 12.24.2.4.2. Calcitonin 12.25. Spain Biosimilars Market Forecast, By Type of Manufacturing 12.25.1. In-house Manufacturing 12.25.2. Contract Manufacturing 12.26. Spain Biosimilars Market Forecast, By Disease 12.26.1. Oncology 12.26.2. Blood Disorders 12.26.3. Chronic Diseases 12.26.4. Autoimmune Diseases 12.26.5. Growth Hormone Deficiency 12.26.6. Infectious Diseases 12.26.7. Other Diseases 12.27. Rest of Europe Biosimilars Market Forecast, By Product 12.27.1. Recombinant Non-glycosylated Proteins 12.27.1.1. Insulin 12.27.1.2. Recombinant Human Growth Hormone 12.27.1.3. Granulocyte Colony-stimulating Factor 12.27.1.4. Interferon 12.27.2. Recombinant Glycosylated Proteins 12.27.2.1. Erythropoietin 12.27.2.2. Monoclonal Antibodies 12.27.2.2.1. Rituximab 12.27.2.2.2. Infliximab 12.27.2.2.3. Adalimumab 12.27.2.2.4. Other Monoclonal Antibodies 12.27.2.3. Follitropin 12.27.2.4. Recombinant Peptides 12.27.2.4.1. Glucagon 12.27.2.4.2. Calcitonin 12.28. Rest of Europe Biosimilars Market Forecast, By Type of Manufacturing 12.28.1. In-house Manufacturing 12.28.2. Contract Manufacturing 12.29. Rest of Europe Biosimilars Market Forecast, By Disease 12.29.1. Oncology 12.29.2. Blood Disorders 12.29.3. Chronic Diseases 12.29.4. Autoimmune Diseases 12.29.5. Growth Hormone Deficiency 12.29.6. Infectious Diseases 12.29.7. Other Diseases 12.30. Europe Biosimilars Market Attractiveness Analysis 12.30.1. By Product 12.30.2. By Type of Manufacturing 12.30.3. By Disease 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Development 13. Asia Pacific Biosimilars Market Analysis 13.1. Key Findings 13.2. Asia Pacific Biosimilars Market Overview 13.3. Asia Pacific Biosimilars Market Value Share Analysis, By Product 13.4. Asia Pacific Biosimilars Market Forecast, By Product 13.4.1. Recombinant Non-glycosylated Proteins 13.4.1.1. Insulin 13.4.1.2. Recombinant Human Growth Hormone 13.4.1.3. Granulocyte Colony-stimulating Factor 13.4.1.4. Interferon 13.4.2. Recombinant Glycosylated Proteins 13.4.2.1. Erythropoietin 13.4.2.2. Monoclonal Antibodies 13.4.2.2.1. Rituximab 13.4.2.2.2. Infliximab 13.4.2.2.3. Adalimumab 13.4.2.2.4. Other Monoclonal Antibodies 13.4.2.3. Follitropin 13.4.2.4. Recombinant Peptides 13.4.2.4.1. Glucagon 13.4.2.4.2. Calcitonin 13.5. Asia Pacific Biosimilars Market Value Share Analysis, By Type of Manufacturing 13.6. Asia Pacific Biosimilars Market Forecast, By Type of Manufacturing 13.6.1. In-house Manufacturing 13.6.2. Contract Manufacturing 13.7. Asia Pacific Biosimilars Market Value Share Analysis, By Disease 13.8. Asia Pacific Biosimilars Market Forecast, By Disease 13.8.1. Oncology 13.8.2. Blood Disorders 13.8.3. Chronic Diseases 13.8.4. Autoimmune Diseases 13.8.5. Growth Hormone Deficiency 13.8.6. Infectious Diseases 13.8.7. Other Diseases 13.9. Asia Pacific Biosimilars Market Value Share Analysis, by Country 13.10. Asia Pacific Biosimilars Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Biosimilars Market Analysis, by Country 13.12. China Biosimilars Market Forecast, By Product 13.12.1. Recombinant Non-glycosylated Proteins 13.12.1.1. Insulin 13.12.1.2. Recombinant Human Growth Hormone 13.12.1.3. Granulocyte Colony-stimulating Factor 13.12.1.4. Interferon 13.12.2. Recombinant Glycosylated Proteins 13.12.2.1. Erythropoietin 13.12.2.2. Monoclonal Antibodies 13.12.2.2.1. Rituximab 13.12.2.2.2. Infliximab 13.12.2.2.3. Adalimumab 13.12.2.2.4. Other Monoclonal Antibodies 13.12.2.3. Follitropin 13.12.2.4. Recombinant Peptides 13.12.2.4.1. Glucagon 13.12.2.4.2. Calcitonin 13.13. China Biosimilars Market Forecast, By Type of Manufacturing 13.13.1. In-house Manufacturing 13.13.2. Contract Manufacturing 13.14. China Biosimilars Market Forecast, By Disease 13.14.1. Oncology 13.14.2. Blood Disorders 13.14.3. Chronic Diseases 13.14.4. Autoimmune Diseases 13.14.5. Growth Hormone Deficiency 13.14.6. Infectious Diseases 13.14.7. Other Diseases 13.15. India Biosimilars Market Forecast, By Product 13.15.1. Recombinant Non-glycosylated Proteins 13.15.1.1. Insulin 13.15.1.2. Recombinant Human Growth Hormone 13.15.1.3. Granulocyte Colony-stimulating Factor 13.15.1.4. Interferon 13.15.2. Recombinant Glycosylated Proteins 13.15.2.1. Erythropoietin 13.15.2.2. Monoclonal Antibodies 13.15.2.2.1. Rituximab 13.15.2.2.2. Infliximab 13.15.2.2.3. Adalimumab 13.15.2.2.4. Other Monoclonal Antibodies 13.15.2.3. Follitropin 13.15.2.4. Recombinant Peptides 13.15.2.4.1. Glucagon 13.15.2.4.2. Calcitonin 13.16. India Biosimilars Market Forecast, By Type of Manufacturing 13.16.1. In-house Manufacturing 13.16.2. Contract Manufacturing 13.17. India Biosimilars Market Forecast, By Disease 13.17.1. Oncology 13.17.2. Blood Disorders 13.17.3. Chronic Diseases 13.17.4. Autoimmune Diseases 13.17.5. Growth Hormone Deficiency 13.17.6. Infectious Diseases 13.17.7. Other Diseases 13.18. Japan Biosimilars Market Forecast, By Product 13.18.1. Recombinant Non-glycosylated Proteins 13.18.1.1. Insulin 13.18.1.2. Recombinant Human Growth Hormone 13.18.1.3. Granulocyte Colony-stimulating Factor 13.18.1.4. Interferon 13.18.2. Recombinant Glycosylated Proteins 13.18.2.1. Erythropoietin 13.18.2.2. Monoclonal Antibodies 13.18.2.2.1. Rituximab 13.18.2.2.2. Infliximab 13.18.2.2.3. Adalimumab 13.18.2.2.4. Other Monoclonal Antibodies 13.18.2.3. Follitropin 13.18.2.4. Recombinant Peptides 13.18.2.4.1. Glucagon 13.18.2.4.2. Calcitonin 13.19. Japan Biosimilars Market Forecast, By Type of Manufacturing 13.19.1. In-house Manufacturing 13.19.2. Contract Manufacturing 13.20. Japan Biosimilars Market Forecast, By Disease 13.20.1. Oncology 13.20.2. Blood Disorders 13.20.3. Chronic Diseases 13.20.4. Autoimmune Diseases 13.20.5. Growth Hormone Deficiency 13.20.6. Infectious Diseases 13.20.7. Other Diseases 13.21. ASEAN Biosimilars Market Forecast, By Product 13.21.1. Recombinant Non-glycosylated Proteins 13.21.1.1. Insulin 13.21.1.2. Recombinant Human Growth Hormone 13.21.1.3. Granulocyte Colony-stimulating Factor 13.21.1.4. Interferon 13.21.2. Recombinant Glycosylated Proteins 13.21.2.1. Erythropoietin 13.21.2.2. Monoclonal Antibodies 13.21.2.2.1. Rituximab 13.21.2.2.2. Infliximab 13.21.2.2.3. Adalimumab 13.21.2.2.4. Other Monoclonal Antibodies 13.21.2.3. Follitropin 13.21.2.4. Recombinant Peptides 13.21.2.4.1. Glucagon 13.21.2.4.2. Calcitonin 13.22. ASEAN Biosimilars Market Forecast, By Type of Manufacturing 13.22.1. In-house Manufacturing 13.22.2. Contract Manufacturing 13.23. ASEAN Biosimilars Market Forecast, By Disease 13.23.1. Oncology 13.23.2. Blood Disorders 13.23.3. Chronic Diseases 13.23.4. Autoimmune Diseases 13.23.5. Growth Hormone Deficiency 13.23.6. Infectious Diseases 13.23.7. Other Diseases 13.24. Rest of Asia Pacific Biosimilars Market Forecast, By Product 13.24.1. Recombinant Non-glycosylated Proteins 13.24.1.1. Insulin 13.24.1.2. Recombinant Human Growth Hormone 13.24.1.3. Granulocyte Colony-stimulating Factor 13.24.1.4. Interferon 13.24.2. Recombinant Glycosylated Proteins 13.24.2.1. Erythropoietin 13.24.2.2. Monoclonal Antibodies 13.24.2.2.1. Rituximab 13.24.2.2.2. Infliximab 13.24.2.2.3. Adalimumab 13.24.2.2.4. Other Monoclonal Antibodies 13.24.2.3. Follitropin 13.24.2.4. Recombinant Peptides 13.24.2.4.1. Glucagon 13.24.2.4.2. Calcitonin 13.25. Rest of Asia Pacific Biosimilars Market Forecast, By Type of Manufacturing 13.25.1. In-house Manufacturing 13.25.2. Contract Manufacturing 13.26. Rest of Asia Pacific Biosimilars Market Forecast, By Disease 13.26.1. Oncology 13.26.2. Blood Disorders 13.26.3. Chronic Diseases 13.26.4. Autoimmune Diseases 13.26.5. Growth Hormone Deficiency 13.26.6. Infectious Diseases 13.26.7. Other Diseases 13.27. Asia Pacific Biosimilars Market Attractiveness Analysis 13.27.1. By Product 13.27.2. By Type of Manufacturing 13.27.3. By Disease 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Development 14. Middle East & Africa Biosimilars Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Biosimilars Market Overview 14.3. Middle East & Africa Biosimilars Market Value Share Analysis, By Product 14.4. Middle East & Africa Biosimilars Market Forecast, By Product 14.4.1. Recombinant Non-glycosylated Proteins 14.4.1.1. Insulin 14.4.1.2. Recombinant Human Growth Hormone 14.4.1.3. Granulocyte Colony-stimulating Factor 14.4.1.4. Interferon 14.4.2. Recombinant Glycosylated Proteins 14.4.2.1. Erythropoietin 14.4.2.2. Monoclonal Antibodies 14.4.2.2.1. Rituximab 14.4.2.2.2. Infliximab 14.4.2.2.3. Adalimumab 14.4.2.2.4. Other Monoclonal Antibodies 14.4.2.3. Follitropin 14.4.2.4. Recombinant Peptides 14.4.2.4.1. Glucagon 14.4.2.4.2. Calcitonin 14.5. Middle East & Africa Biosimilars Market Value Share Analysis, By Type of Manufacturing 14.6. Middle East & Africa Biosimilars Market Forecast, By Type of Manufacturing 14.6.1. In-house Manufacturing 14.6.2. Contract Manufacturing 14.7. Middle East & Africa Biosimilars Market Value Share Analysis, By Disease 14.8. Middle East & Africa Biosimilars Market Forecast, By Disease 14.8.1. Oncology 14.8.2. Blood Disorders 14.8.3. Chronic Diseases 14.8.4. Autoimmune Diseases 14.8.5. Growth Hormone Deficiency 14.8.6. Infectious Diseases 14.8.7. Other Diseases 14.9. Middle East & Africa Biosimilars Market Value Share Analysis, by Country 14.10. Middle East & Africa Biosimilars Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Biosimilars Market Analysis, by Country 14.12. GCC Biosimilars Market Forecast, By Product 14.12.1. Recombinant Non-glycosylated Proteins 14.12.1.1. Insulin 14.12.1.2. Recombinant Human Growth Hormone 14.12.1.3. Granulocyte Colony-stimulating Factor 14.12.1.4. Interferon 14.12.2. Recombinant Glycosylated Proteins 14.12.2.1. Erythropoietin 14.12.2.2. Monoclonal Antibodies 14.12.2.2.1. Rituximab 14.12.2.2.2. Infliximab 14.12.2.2.3. Adalimumab 14.12.2.2.4. Other Monoclonal Antibodies 14.12.2.3. Follitropin 14.12.2.4. Recombinant Peptides 14.12.2.4.1. Glucagon 14.12.2.4.2. Calcitonin 14.13. GCC Biosimilars Market Forecast, By Type of Manufacturing 14.13.1. In-house Manufacturing 14.13.2. Contract Manufacturing 14.14. GCC Biosimilars Market Forecast, By Disease 14.14.1. Oncology 14.14.2. Blood Disorders 14.14.3. Chronic Diseases 14.14.4. Autoimmune Diseases 14.14.5. Growth Hormone Deficiency 14.14.6. Infectious Diseases 14.14.7. Other Diseases 14.15. South Africa Biosimilars Market Forecast, By Product 14.15.1. Recombinant Non-glycosylated Proteins 14.15.1.1. Insulin 14.15.1.2. Recombinant Human Growth Hormone 14.15.1.3. Granulocyte Colony-stimulating Factor 14.15.1.4. Interferon 14.15.2. Recombinant Glycosylated Proteins 14.15.2.1. Erythropoietin 14.15.2.2. Monoclonal Antibodies 14.15.2.2.1. Rituximab 14.15.2.2.2. Infliximab 14.15.2.2.3. Adalimumab 14.15.2.2.4. Other Monoclonal Antibodies 14.15.2.3. Follitropin 14.15.2.4. Recombinant Peptides 14.15.2.4.1. Glucagon 14.15.2.4.2. Calcitonin 14.16. South Africa Biosimilars Market Forecast, By Type of Manufacturing 14.16.1. In-house Manufacturing 14.16.2. Contract Manufacturing 14.17. South Africa Biosimilars Market Forecast, By Disease 14.17.1. Oncology 14.17.2. Blood Disorders 14.17.3. Chronic Diseases 14.17.4. Autoimmune Diseases 14.17.5. Growth Hormone Deficiency 14.17.6. Infectious Diseases 14.17.7. Other Diseases 14.18. Rest of Middle East & Africa Biosimilars Market Forecast, By Product 14.18.1. Recombinant Non-glycosylated Proteins 14.18.1.1. Insulin 14.18.1.2. Recombinant Human Growth Hormone 14.18.1.3. Granulocyte Colony-stimulating Factor 14.18.1.4. Interferon 14.18.2. Recombinant Glycosylated Proteins 14.18.2.1. Erythropoietin 14.18.2.2. Monoclonal Antibodies 14.18.2.2.1. Rituximab 14.18.2.2.2. Infliximab 14.18.2.2.3. Adalimumab 14.18.2.2.4. Other Monoclonal Antibodies 14.18.2.3. Follitropin 14.18.2.4. Recombinant Peptides 14.18.2.4.1. Glucagon 14.18.2.4.2. Calcitonin 14.19. Rest of Middle East & Africa Biosimilars Market Forecast, By Type of Manufacturing 14.19.1. In-house Manufacturing 14.19.2. Contract Manufacturing 14.20. Rest of Middle East & Africa Biosimilars Market Forecast, By Disease 14.20.1. Oncology 14.20.2. Blood Disorders 14.20.3. Chronic Diseases 14.20.4. Autoimmune Diseases 14.20.5. Growth Hormone Deficiency 14.20.6. Infectious Diseases 14.20.7. Other Diseases 14.21. Middle East & Africa Biosimilars Market Attractiveness Analysis 14.21.1. By Product 14.21.2. By Type of Manufacturing 14.21.3. By Disease 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Development 15. South America Biosimilars Market Analysis 15.1. Key Findings 15.2. South America Biosimilars Market Overview 15.3. South America Biosimilars Market Value Share Analysis, By Product 15.4. South America Biosimilars Market Forecast, By Product 15.4.1. Recombinant Non-glycosylated Proteins 15.4.1.1. Insulin 15.4.1.2. Recombinant Human Growth Hormone 15.4.1.3. Granulocyte Colony-stimulating Factor 15.4.1.4. Interferon 15.4.2. Recombinant Glycosylated Proteins 15.4.2.1. Erythropoietin 15.4.2.2. Monoclonal Antibodies 15.4.2.2.1. Rituximab 15.4.2.2.2. Infliximab 15.4.2.2.3. Adalimumab 15.4.2.2.4. Other Monoclonal Antibodies 15.4.2.3. Follitropin 15.4.2.4. Recombinant Peptides 15.4.2.4.1. Glucagon 15.4.2.4.2. Calcitonin 15.5. South America Biosimilars Market Value Share Analysis, By Type of Manufacturing 15.6. South America Biosimilars Market Forecast, By Type of Manufacturing 15.6.1. In-house Manufacturing 15.6.2. Contract Manufacturing 15.7. South America Biosimilars Market Value Share Analysis, By Disease 15.8. South America Biosimilars Market Forecast, By Disease 15.8.1. Oncology 15.8.2. Blood Disorders 15.8.3. Chronic Diseases 15.8.4. Autoimmune Diseases 15.8.5. Growth Hormone Deficiency 15.8.6. Infectious Diseases 15.8.7. Other Diseases 15.9. South America Biosimilars Market Value Share Analysis, by Country 15.10. South America Biosimilars Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Biosimilars Market Analysis, by Country 15.12. Brazil Biosimilars Market Forecast, By Product 15.12.1. Recombinant Non-glycosylated Proteins 15.12.1.1. Insulin 15.12.1.2. Recombinant Human Growth Hormone 15.12.1.3. Granulocyte Colony-stimulating Factor 15.12.1.4. Interferon 15.12.2. Recombinant Glycosylated Proteins 15.12.2.1. Erythropoietin 15.12.2.2. Monoclonal Antibodies 15.12.2.2.1. Rituximab 15.12.2.2.2. Infliximab 15.12.2.2.3. Adalimumab 15.12.2.2.4. Other Monoclonal Antibodies 15.12.2.3. Follitropin 15.12.2.4. Recombinant Peptides 15.12.2.4.1. Glucagon 15.12.2.4.2. Calcitonin 15.13. Brazil Biosimilars Market Forecast, By Type of Manufacturing 15.13.1. In-house Manufacturing 15.13.2. Contract Manufacturing 15.14. Brazil Biosimilars Market Forecast, By Disease 15.14.1. Oncology 15.14.2. Blood Disorders 15.14.3. Chronic Diseases 15.14.4. Autoimmune Diseases 15.14.5. Growth Hormone Deficiency 15.14.6. Infectious Diseases 15.14.7. Other Diseases 15.15. Mexico Biosimilars Market Forecast, By Product 15.15.1. Recombinant Non-glycosylated Proteins 15.15.1.1. Insulin 15.15.1.2. Recombinant Human Growth Hormone 15.15.1.3. Granulocyte Colony-stimulating Factor 15.15.1.4. Interferon 15.15.2. Recombinant Glycosylated Proteins 15.15.2.1. Erythropoietin 15.15.2.2. Monoclonal Antibodies 15.15.2.2.1. Rituximab 15.15.2.2.2. Infliximab 15.15.2.2.3. Adalimumab 15.15.2.2.4. Other Monoclonal Antibodies 15.15.2.3. Follitropin 15.15.2.4. Recombinant Peptides 15.15.2.4.1. Glucagon 15.15.2.4.2. Calcitonin 15.16. Mexico Biosimilars Market Forecast, By Type of Manufacturing 15.16.1. In-house Manufacturing 15.16.2. Contract Manufacturing 15.17. Mexico Biosimilars Market Forecast, By Disease 15.17.1. Oncology 15.17.2. Blood Disorders 15.17.3. Chronic Diseases 15.17.4. Autoimmune Diseases 15.17.5. Growth Hormone Deficiency 15.17.6. Infectious Diseases 15.17.7. Other Diseases 15.18. Rest of South America Biosimilars Market Forecast, By Product 15.18.1. Recombinant Non-glycosylated Proteins 15.18.1.1. Insulin 15.18.1.2. Recombinant Human Growth Hormone 15.18.1.3. Granulocyte Colony-stimulating Factor 15.18.1.4. Interferon 15.18.2. Recombinant Glycosylated Proteins 15.18.2.1. Erythropoietin 15.18.2.2. Monoclonal Antibodies 15.18.2.2.1. Rituximab 15.18.2.2.2. Infliximab 15.18.2.2.3. Adalimumab 15.18.2.2.4. Other Monoclonal Antibodies 15.18.2.3. Follitropin 15.18.2.4. Recombinant Peptides 15.18.2.4.1. Glucagon 15.18.2.4.2. Calcitonin 15.19. Rest of South America Biosimilars Market Forecast, By Type of Manufacturing 15.19.1. In-house Manufacturing 15.19.2. Contract Manufacturing 15.20. Rest of South America Biosimilars Market Forecast, By Disease 15.20.1. Oncology 15.20.2. Blood Disorders 15.20.3. Chronic Diseases 15.20.4. Autoimmune Diseases 15.20.5. Growth Hormone Deficiency 15.20.6. Infectious Diseases 15.20.7. Other Diseases 15.21. South America Biosimilars Market Attractiveness Analysis 15.21.1. By Product 15.21.2. By Type of Manufacturing 15.21.3. By Disease 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Development 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Pfizer 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Sandoz International 16.3.3. Teva Pharmaceuticals 16.3.4. Amgen 16.3.5. Biocon 16.3.6. Dr. Reddy’s Laboratories 16.3.7. Celltrion 16.3.8. Samsung Biologics 16.3.9. Eli Lily & Company 16.3.10. Hospira Inc. 16.3.11. ctavis, Inc 16.3.12. Teva Pharmaceutical Industries Ltd. 16.3.13. Cipla Ltd. 16.3.14. Stada Arzneimittel Ag 16.3.15. Wockhardt Ltd 16.3.16. Mylan, Inc. 16.3.17. Biocad 16.3.18. Coherus Bioscience 16.3.19.Boehringer Ingelheim 16.3.20.Fresenius Kabi AG 17. Primary Key Insights

About This Report

Report ID 31668
Category Biotechnology
Published Date June 2019
Updated Date Dec 2020
Contact Us